Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LY 03021

Next Previous
X
Search
Drug Profile

LY 03021

Alternative Names: LY-03021

Latest Information Update: 10 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Luye Pharma Group
  • Class Antidepressants; Small molecules
  • Mechanism of Action Dopamine plasma membrane transport protein antagonists; GABA A receptor positive allosteric modulators; Norepinephrine plasma membrane transport protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Major depressive disorder

Most Recent Events

  • 15 Nov 2024 Luye Phrama Group plans a clinical trial in Major Depressive disorder in China
  • 11 Nov 2024 Preclinical trials in Major depressive disorder in China (unspecified route) before November 2024 (9429762
  • 11 Nov 2024 Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) approves the IND application for LY 03021 in Major Depressive Disorder

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top